Dear Eric: I’m pretty sure I should seek therapy. As a longtime first responder with probable PTSD, plus recent marital issues and the recent deaths of a number of close loved ones, I feel the need to ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Marc Herstand has been on the forefront of a campaign to ban mental health professionals in Wisconsin from counseling clients ...

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.

Neurological conditions are now the leading cause of ill health worldwide, yet remain an enigma. Meet the patients who baffle ...

A purification ceremony in Bali is trending on TikTok. While some locals welcome the interest, others are concerned that ...

Couples often don't realize they have the power to learn simple tools to defuse conflict and listen deeply. Our conflict can ...

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

Regulatory submissions for subcutaneous Sarclisa are planned for 2025, with ongoing studies exploring its use in various ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...